Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
05/31/20241:42AMPR Newswire (Canada)À l'échelle mondiale, un patient sur six est préoccupé par les coûts du dépistage du cancer colorectal
05/31/20241:40AMPR Newswire (US)Vaimo recognized as one of Deloitte's Best Managed Companies for the third consecutive year in 2024
05/31/20241:35AMGlobeNewswire Inc.Multitude SE: Fixed-income investor meetingsTG:FRUMultitude SE
05/31/20241:35AMGlobeNewswire Inc.Multitude SE: Fixed-income investor meetingsXE:FRUMultitude SE
05/31/20241:34AMPR Newswire (Canada)Trip.com Reveals Growing Demand for Personalisation in the Attractions & Tours Sector at Envision 2024
05/31/20241:34AMPR Newswire (US)Trip.com Reveals Growing Demand for Personalisation in the Attractions & Tours Sector at Envision 2024
05/31/20241:31AMAlliance NewsAlliance NewsGET READY: CMO Group and JD Sports full-year results at 0700 BST
05/31/20241:30AMAlliance NewsAlliance NewsAlliance News UK - start of day
05/31/20241:30AMGlobeNewswire Inc.BGHL (GBP): NAV(s)LSE:BGHSBoussard & Gavaudan Holding Limited
05/31/20241:30AMGlobeNewswire Inc.Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en coursEU:ALCOXNicox SA
05/31/20241:30AMGlobeNewswire Inc.BGHL (EUR): NAV(s)LSE:BGHLBoussard & Gavaudan Holding Limited
05/31/20241:30AMGlobeNewswire Inc.BGHL (GBP): NAV(s)EU:BGHSBoussard and Gavaudan Holding
05/31/20241:30AMGlobeNewswire Inc.Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en coursLSE:0RCQNicox Sa
05/31/20241:30AMGlobeNewswire Inc.Nicox annonce l’organisation d’un webcast pour ses actionnaires le 6 juin 2024 à 18h00 CET à l’occasion de son augmentation du capital déjà en coursTG:NXOANicox SA
05/31/20241:30AMGlobeNewswire Inc.BGHL (EUR): NAV(s)EU:BGHLBoussard And Gavaudan Holding Limited
05/31/20241:30AMGlobeNewswire Inc.Baosheng Media Group Holdings Limited Announces Filing of Current Report on Form 6-K with the SEC regarding Pending Legal ProceedingNASDAQ:BAOSBaosheng Media Group Holdings Ltd
05/31/20241:17AMPR Newswire (US)MoonFox Analysis | How WeChat Channels Burdens of Tencent's Hopes for the Future Amidst Rapid CommercializationNASDAQ:JGAurora Mobile Ltd
05/31/20241:07AMAlliance NewsAlliance NewsJapan's monthly retail sales rebound in April; unemployment stable
05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOBIT:1SANSanofi
05/31/20241:05AMGlobeNewswire Inc.Net asset value of the EfTEN United Property Fund as of 30.04.2024
05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDBIT:SANFSanofi
05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOEU:SANSanofi
05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOBIT:SANFSanofi
05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDBIT:1SANSanofi
05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDEU:SANSanofi
05/31/20241:05AMGlobeNewswire Inc.Communiqué de presse : Le CHMP recommande l'approbation de Dupixent dans l'UE pour le traitement des patients atteints de BPCOTG:SNWSanofi
05/31/20241:05AMGlobeNewswire Inc.Press Release: Dupixent recommended for EU approval by the CHMP to treat patients with COPDTG:SNWSanofi
05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDNASDAQ:REGNRegeneron Pharmaceuticals Inc
05/31/20241:05AMGlobeNewswire Inc.Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Patients with COPDEU:SANSanofi